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Abstract
Objective: Arterial and ventricular stiffening are characteristics of diabetes and aging which confer significant morbidity and
mortality; advanced glycation endproducts (AGE) are implicated in this stiffening pathophysiology. We examined the
association between HbA1c, an AGE, with arterial and ventricular stiffness measures in older individuals without diabetes.
Research Design & Methods: Baseline HbA1c was measured in 830 participants free of diabetes defined by fasting glucose
or medication use in the Cardiovascular Health Study, a population-based cohort study of adults aged $65 years. We
performed cross-sectional analyses using baseline exam data including echocardiography, ankle and brachial blood
pressure measurement, and carotid ultrasonography. We examined the adjusted associations between HbA1c and multiple
arterial and ventricular stiffness measures by linear regression models and compared these results to the association of
fasting glucose (FG) with like measures.
Results: HbA1c was correlated with fasting and 2-hour postload glucose levels (r=0.21; p,0.001 for both) and positively
associated with greater body-mass index and black race. In adjusted models, HbA1c was not associated with any measure of
arterial or ventricular stiffness, including pulse pressure (PP), carotid intima-media thickness, ankle-brachial index, end-
arterial elastance, or left ventricular mass (LVM). FG levels were positively associated with systolic, diastolic and PP and LVM.
Conclusions: In this sample of older adults without diabetes, HbA1c was not associated with arterial or ventricular stiffness
measures, whereas FG levels were. The role of AGE in arterial and ventricular stiffness in older adults may be better assessed
using alternate AGE markers.
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Introduction
Increased arterial and ventricular stiffness are hallmarks of
aging and its attendant comorbidity [1]. Clinical measures of
arterial stiffness, such as elevated pulse pressure (PP) and isolated
systolic hypertension (ISH), are associated with greater risk for
cardiovascular disease (CVD), chronic kidney disease, dementia,
and mortality. Ventricular stiffness is associated with left ventric-
ular hypertrophy (LVH) and delayed early diastolic filling which,
in turn, increase the risk of heart failure (HF), and death [2].
People with diabetes, both young and old, carry an even higher
risk of arterial and ventricular stiffness and its cardiovascular
sequelae [3,4].
Age-associated arterial changes include increased intima-medial
thickness (IMT), smooth muscle hypertrophy, collagen accrual and
cross-linking, fibrosis, and inflammation [1]. These aging changes
are, in part, due to time-related exposure to and accrual of
advanced glycation endproducts (AGE), irreversibly glycated
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- .proteins, which, in turn, stimulate systemic inflammation, oxida-
tive stress, fibrosis, extracellular matrix remodeling, tissue injury
modulation and lipid deposition in the arterial wall [5]. Elevated
blood glucose concentrations favor AGE formation. Thus, AGE
may play an important role in arterial and ventricular stiffness
associated with aging even in individuals without diabetes, but
with evidence of elevated blood glucose levels.
Glycosylated hemoglobin (HbA1c) is an AGE that serves
clinically as a marker of average glycemia in individuals with
diabetes and recently has been added as a diagnostic criterion for
diabetes [6]. This is based on several large cohort studies
demonstrating the positive association of HbA1c levels with
incident cardiovascular events, stroke and mortality in those with
and, in some cases, those without diabetes [7,8,9,10]. HbA1c levels
are also positively correlated with subclinical arterial disease
(carotid intimal medial thickness [cIMT] and ankle-brachial index)
in people with diabetes [11,12], but the MESA cohort found only
a weak correlation between HbA1c and cIMT and coronary
calcium scores in subjects without diabetes (mean age 63610 yrs)
[13]. As an AGE of hemoglobin in red blood cells (half-life of
approximately 100 days), HbA1c may not reflect ambient glycemia
over longer time periods. Nevertheless, it represents a potential
useful biomarker with which to evaluate whether AGE are
associated with measures of arterial and ventricular stiffness. To
our knowledge, no previous large-scale study has comprehensively
evaluated the association of the full range of values of this AGE
with multiple non-invasive measures of arterial and ventricular
stiffness, especially in a population-based study of older adults.
To address these issues, we examined the cross-sectional
associations of HbA1c with several markers of ventricular and
arterial stiffness and atherosclerosis among older adults free of
prevalent diabetes in the Cardiovascular Health Study (CHS).
Methods
Study Population
CHS is a NHLBI-sponsored, population-based, longitudinal
study of clinical and subclinical CVD and its risk factors among
5888 community-dwelling older adults in the U.S. [14,15]
Utilizing Medicare eligibility lists, 5,201 ambulatory, non-institu-
tionalized men and women were contacted and enrolled from four
U.S. communities (Allegheny County, Pennsylvania; Forsyth
County, North Carolina; Sacramento County, California; and
Washington County, Maryland) in 1989–90. The Wake Forest
University Health Sciences Institutional Review Board (IRB),
University of California Davis IRB, Johns Hopkins Bloomberg
School of Public Health IRB, and University of Pittsburgh IRB
approved the study, and all participants provided written informed
consent. Participants underwent a standardized clinic examina-
tion, laboratory evaluation, echocardiography, and questionnaires
on health status, medical history, and cardiovascular risk factors
[16,17].
HbA1c was measured in a substudy of 1,094 participants of the
1,305 recruited from Forsyth County at the baseline examination
in 1989–90. Of these, we excluded 62 participants with chronic
atrial fibrillation, 39 with moderate or severe mitral regurgitation,
4 with moderate or severe aortic stenosis, and 6 with aortic
insufficiency, in whom echocardiographic measures were consid-
ered less reliable measures of arterial or ventricular stiffness. To
minimize the influence of outliers and potentially errant values, we
also excluded 14 participants with values above an arbitrary
HbA1c threshold of 14%. Lastly, we excluded 8 participants
missing information on diabetes status.
Because our primary interest was in the association of HbA1c
with vascular stiffness among non-diabetic individuals, we
excluded 131 persons with prevalent diabetes on the basis of the
previous definition of diabetes as fasting glucose$126 mg/dL or
use of insulin or oral hypoglycemic agents, providing an analytic
sample of 830. Participants with prevalent diabetes by this
definition were included as a separate category in secondary
analyses in which HbA1c was categorized in approximate tertiles.
In those analyses, the threshold for the highest tertile was 6.5%, so
that the highest category corresponded to the current diagnostic
threshold for diabetes, creating categories of low and intermediate
HbA1c, high HbA1c but without other criteria for diabetes, and
diabetes by previous criteria.
Measurement of HbA1c
HbA1c was measured in previously frozen whole blood samples
from 1989–90 stored at 270uC. A standard kit affinity column
method was employed (normal values ranged from 2.9–5.1%) and
standardized against high pressure liquid chromatography proce-
dures. The Wake Forest University Clinical Pathology Depart-
ment performed these assays with regular monitoring for quality
assurance.
Measurement of Arterial and Ventricular Stiffness and
Atherosclerosis
We tested the relationship between HbA1c and several non-
invasive peripheral measures of arterial stiffness, including PP and
SBP. Additional estimates of total arterial stiffness, (effective
arterial elastance (Ea), PP/Stroke Volume) were calculated
utilizing echocardiographic data described later. Finally, we
included two measures of subclinical vascular disease – carotid
IMT and ankle-brachial index (ABI), which we considered to
reflect both arterial stiffness and atherosclerosis.
Study technicians measured resting brachial blood pressure
according to a standardized protocol [18], and we used the
average of the first and second readings for systolic and diastolic
values. Pulse pressure was calculated as the difference between
systolic and diastolic values. Vascular ultrasound of the internal
and common carotid arteries was used to determine IMT [19]. We
determined carotid IMT as the mean of the maximum wall
thickness for near and far walls on both the left and right carotid
arteries. We used both internal and common carotid IMT in our
analyses. We calculated ABI as the ratio of the lower of ankle
pressures taken in the right and left legs divided by the average of
two right arm blood pressure measurements [20]. Individuals with
ABI.1.40 were excluded from this analysis (n=11).
Participants underwent routine M-mode, 2-dimensional, and
Doppler echocardiographic examinations at baseline using the
Toshiba SSH-160A (Toshiba American Medical Systems, Tustin,
CA) equipped with 2.5 MHz and 3.75 MHz transducers [17].
American Society of Echocardiography recommendations were
used to guide two-dimensionally directed M-mode measurements
of LV mass [21]. Mitral flow velocity including early and late
(atrial) peak filling and regurgitation was assessed by Doppler.(21)
Stroke volume (SV) was estimated using the left ventricular
velocity-time integral and calculated outflow tract area as
previously described [22]. Trained readers interpreted stored
echocardiographic images centrally at the CHS Echo Reading
Center. Quality control measures included standardized training
of sonographers and readers, observation of technicians by a
trained echocardiographer, periodic blind duplicate readings,
phantom studies, and quality control adults.
Based upon echocardiographic measurements, we calculated
several variables related to arterial and ventricular stiffness.
HbA1c and Arterial and Ventricular Stiffness
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compliance was calculated using estimated end-systolic pressure
(ESP) as ([2*SBP]-DBP)/3 and stroke volume index (SVI) as SV/
body surface area (BSA); Ea was calculated as the ratio of ESP to
SVI. Total arterial load (PP/SV) was calculated from brachial PP
and echocardiographic SV. Ventricular structure was represented
by left ventricular (LV) mass and ventricular stiffness by the ratio
of early to atrial filling (E/A ratio) on mitral pulsed Doppler inflow
tracings and end-systolic elastance (Ees) was calculated as the ratio
of ESP to LV end-systolic volume (by echocardiogram)/BSA.
Other Measurements
Body mass index (BMI) was calculated from technician-
measured height and weight. Participants were classified as
smokers if they reported smoking within the previous 30 days or
identified themselves as smokers. Former and never smokers were
classified based on self-reported smoking status and reported no
cigarette smoking in the past 30 days. Blood collection, processing,
and laboratory methods for fasting glucose, lipid measurements,
C-reactive protein, and creatinine are described elsewhere [16,23].
Participants also underwent standard oral glucose tolerance testing
(OGTT) at baseline. Study staff performed detailed medication
inventories to obtain information on medication use [24]. We
defined hypertension as SBP$140 mmHg, DBP$90 mmHg, or
the use of hypertension medications.
Statistical Analysis
In descriptive analyses, we categorized HbA1c into approximate
tertiles and evaluated differences across categories using analysis of
variance for continuous variables or x
2 tests for categorical
variables. We used linear regression models to examine the
association between HbA1c as continuous variable and measures of
arterial and ventricular stiffness, initially adjusting for age, gender,
and race. For comparison, we then repeated these models
substituting fasting blood glucose for HbA1c. The various outcome
measures were standardized (i.e., expressed in 1-standard devia-
tion increments, which were the equivalent of 1% in HbA1c and
10 mg/dl in fasting blood glucose) for comparability across
measures. In multivariable models, we further adjusted for BMI,
smoking status, use of antihypertensive medication, use of lipid-
lowering medication, and levels of total cholesterol, high-density
lipoprotein cholesterol, C-reactive protein, and creatinine. The
model for LV mass was also adjusted for BSA.
We next examined the association between categories of HbA1c
and dichotomized measures of subclinical disease using logistic
regression. We adjusted for the same covariates as in linear
regression models and used previously established cutpoints for
IMT (the 80
th percentile), ABI (0.9), and blood pressure
(systolic.140; diastolic.90 mm Hg) to categorize subclinical
disease. We also examined these same measures of subclinical
disease in those with prevalent diabetes defined by glucose or
medication use (n=131) for comparative purposes.
We also determined total glycated hemoglobin, calculated as the
product of HbA1c multiplied by total hemoglobin [25], but this
was highly correlated with HbA1c itself (r 0.85) and did not yield
materially different associations than HbA1c with other glycemic
measures. Based upon the possibility of sex-specific associations of
HbA1c with subclinical disease, we examined interactions of sex
and HbA1c on measures of vascular and ventricular stiffness, but
none of these were significant (p.0.077).
Analyses were performed using STATA 10.1 (College Station,
Texas). A.K. and M.L.B. had full access to all data and assumes
responsibility for data analyses.
Results
Table 1 displays the characteristics of eligible participants
according to categories of HbA1c. Compared to the lowest
category, those with higher HbA1c were more often black, had
greater BMI, and had higher CRP concentrations. Participants
with higher HbA1c also had greater LV mass, while other vascular
measurements were similar across HbA1c categories in bivariate
analysis. HbA1c was moderately correlated with both fasting and
2-hour glucose levels (Pearson r 0.21; p,0.001 for both).
Table 2 shows the associations of HbA1c with multiple measures
of vascular and ventricular stiffness. In both unadjusted and
adjusted models, we did not observe any significant associations of
measures of vascular stiffness and HbA1c. There was an association
of borderline statistical significance with internal carotid IMT in
age-, gender-, and race-adjusted models; however, this appeared
to be mainly confounded by the positive associations of HbA1c
with BMI, smoking status, and C-reactive protein and its inverse
association with high-density lipoprotein cholesterol, so was
attenuated and no longer statistically significant in the final
adjusted model. Sensitivity analyses additionally adjusted for
weight loss/previous BMI or excluding participants on hypogly-
cemic medications did not render any significant relationships. In
contrast to HbA1c, fasting blood glucose was significantly positively
associated with SBP, DBP, PP and LV mass in the multivariate
model.
Table 3 shows the association (odds ratios) of categories of
HbA1c with carotid IMT, ABI, and hypertension, as well as the
category of prevalent diabetes defined by fasting glucose or
medication use. HbA1c was not associated with any of these in
directions consistent with greater stiffness, and paradoxically, it
was associated with a lower prevalence of low ABI, although it was
not associated with ABI in linear analyses shown in Table 2. In
contrast, those with prevalent diabetes defined by glucose or
medication had a substantially higher prevalence of hypertension
in the multivariable model compared to the reference group. The
prevalence of common carotid IMT $80% was also modestly
higher among participants with diabetes, but this increase was not
statistically significant in the fully adjusted model. No significant
increases in prevalence were seen for internal carotid IMT $80%
or ABI,0.9 among those with prevalent diabetes defined by
medication use or fasting glucose.
Discussion
In this cross-sectional study of community-living, older adults,
blood values of HbA1c were not associated with measures of
arterial or ventricular stiffness. In contrast, systolic, diastolic, and
pulse pressures and LV mass were positively associated with fasting
blood glucose. Thus, it would appear that as a relatively short-lived
AGE, HbA1c may not serve well as a biomarker for early
subclinical atherosclerotic or hypertensive changes in older non-
adults without diabetes.
This finding contrasts with the positive association of HbA1c and
carotid IMT and ABI in subjects with known diabetes of the ARIC
cohort, reflecting the possible importance of the duration of
hyperglycemia exposure [11,12]. Consistent with this hypothesis,
only a weakly positive association between HbA1c and common
and internal cIMT was observed in those without known diabetes
in MESA. Although this relationship was not seen in our cohort, it
is important to note that CHS subjects were significantly older and
this measure of HbA1c was performed late in life. This may also
explain the lack of association of HbA1c with incident clinical
cardiovascular events in CHS [26].
HbA1c and Arterial and Ventricular Stiffness
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early biomarker for subclinical cardiovascular disease is its
relatively rapid turnover of months rather than years due to the
limited half-life of erythrocytes. This stands in contrast to the
glycation of structural proteins such a collagen, a major
component of vascular and ventricular structures, which renders
them resistant to hydrolysis resulting in an overabundance of
crosslinked proteins. As a result, single levels of HbA1c, even if
well measured, may not necessarily reflect long-term AGE
accumulation. Moreover, how closely correlated serum HbA1c
and structural glycated proteins are remains unclear. Future
studies using circulating AGEs with longer half-lives, such as
carboxymethyl and carboxyethyl lysine, may shed light on this
topic [27].
The strongly positive associations that we report between fasting
blood glucose and systolic, diastolic, and pulse pressures support
the theory that elevated blood glucose, possibly through AGEs,
impact arterial stiffness, a prominent feature of diabetes and aging.
The positive association between fasting blood glucose and LV
mass are also consistent with findings in animal models in which
induced diabetes leads to increased ventricular pressure, myocyte
hypertrophy, and collagen accrual, all mediated by AGEs [28].
Table 1. Characteristics of Wake Forest CHS Participants without Diabetes Defined by Glucose or Medication, According to
Categories of HbA1c.
Category of HbA1c
3.7–5.6% 5.7–6.4% 6.5–12.8% P value
Median HBA1c 5.3 6.0 6.9
(n=278) (n=293) (n=259)
Demographics
Age (yrs) 71.8 (5.3) 71.7 (5.1) 72.3 (5.4) 0.22
Male 118 (42.5%) 117 (36.6%) 89 (38.4%) 0.33
Black 11 (4.0%) 19 (5.9%) 30 (12.9%) ,0.001
Current smoker 35 (12.6%) 39 (12.2%) 47 (20.3%) 0.02
Risk Factors
Body-mass index (kg/m
2) 25.0 (4.6) 25.3 (3.9) 26.5 (4.3) ,0.001
Total cholesterol (mg/dl) 204.8 (35.6) 209.9 (36.6) 211.4 (38.2) 0.09
HDL cholesterol (mg/dl) 55.4 (16.4) 54.2 (16.3) 52.2 (13.1) 0.07
Systolic blood pressure (mmHg) 135.0 (21.6) 133.3 (21.2) 137.4 (19.7) 0.08
Diastolic blood pressure (mmHg) 80.0 (10.4) 71.2 (10.5) 73.1 (10.1) 0.09
Fasting glucose (mg/dL) 96.7 (9.4) 97.9 (9.1) 102.2 (9.7) ,0.001
2-hour glucose (mg/dL) 124.5 (34.5) 132.2 (44.2) 152.6 (48.3) ,0.001
Creatinine (mg/dl) 1.03 (0.25) 1.03 (0.25) 1.05 (0.35) 0.56
Vascular Measures
Pulse pressure (mmHg) 63.0 (18.2) 62.1 (17.4) 64.2 (16.9) 0.36
Common carotid IMT (mm) 1.03 (0.20) 1.03 (0.22) 1.05 (0.20) 0.68
Internal carotid IMT (mm) 1.33 (0.51) 1.33 (0.55) 1.43 (0.55) 0.06
Ankle brachial index 1.08 (0.15) 1.09 (0.14) 1.08 (0.14) 0.84
ABI,.9 (vs. $.9–1.4) 26 (10.0%) 25 (8.0%) 18 (7.9%) 0.63
Ventricular Measures
Left ventricular mass (gm) 144.6 (28.1) 143.0 (28.6) 149.9 (30.0) 0.02
E/A ratio 0.92 (0.28) 0.95 (0.32) 1.26 (5.4) 0.34
Mixed Measures
Pulse pressure/stroke volume 0.83 (0.31) 0.82 (0.28) 0.85 (0.30) 0.64
Effective-Arterial Elastance (esp/svi) 1.50 (0.46) 1.47 (0.40) 1.54 (0.42) 0.28
Ratio of End-Arterial to End-Systolic Elastance 0.25 (0.09) 0.24 (0.09) 0.24 (0.10) 0.55
Prevalent Diagnoses
Hypertension 158 (56.8%) 173 (54.1%) 147 (63.4%) 0.09
Stroke 13 (4.7%) 5 (1.6%) 5 (2.2%) 0.06
Coronary Heart Disease 55 (19.8%) 41 (12.8%) 38 (16.4%) 0.07
Chronic Kidney Disease (eGFR,60) 25 (9.9%) 37 (13.0%) 41 (20.0%) 0.007
Congestive Heart Failure 5 (1.8%) 6 (1.9%) 3 (1.3%) 0.86
Data are means (6 standard deviations) or proportions.
doi:10.1371/journal.pone.0047941.t001
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measures of blood AGEs that can be applied to epidemiological
settings to evaluate their potential as early biomarkers of
subclinical atherosclerotic disease and early arterial and ventric-
ular stiffening, not only in persons with diabetes, but also among
older individuals in general population. The importance of
identifying a long-term AGE measure is twofold: (1) to elucidate
the pathophysiology which renders arterial and ventricular
stiffness a prominent cause of morbidity and mortality in older
adults, and (2) in those with diabetes and to identify targets for
therapy to reduce stiffness. Novel therapeutics that reverse AGE
crosslinks have been tested but are not currently available [29].
Given the rapidly expanding population of older adults and
prevalence of diabetes, and the burden of cardiovascular disease in
these populations, the relationship of long-term AGE with vascular
stiffness should be a high priority for future research.
An implication of our findings relates to the adoption of HbA1c
as a diagnostic tool for diabetes. The choice of 6.5% as the
threshold for diagnosis results in great part from the fairly linear
cross-sectional association of HbA1c with prevalence of retinopa-
thy that begins at that level [6]. The third category of HbA1c in
our analyses (approximately the upper tertile of HbA1c) corre-
sponds to the subset of individuals who would be classified as
having diabetes only by the HbA1c criterion. This criterion
appears useful even in those without known diabetes in predicting
future risk of diabetes, coronary heart disease, stroke and death in
other cohorts [10]. However, our findings of a similar degree of
vascular stiffness across the three HbA1c tertiles in CHS suggests
caution in using HbA1c as a surrogate marker for subclinical
atherosclerotic and microvascular disease in older adults without
known diabetes.
One of the strengths of CHS is the large and diverse group of
subclinical vascular phenotypes available. Despite the availability
of several measures, we found no discernible association between
HbA1c and any outcome, whether related to blood pressure,
ventricular mass, ventricular stiffness, or vascular stiffness, but
were able to corroborate the elevated prevalence of hypertension
in CHS participants with prevalent diabetes compared to those
without diabetes in the lowest HbA1c category.
Our study has limitations. We relied on single measures of both
HbA1c and outcomes in this cross-sectional analysis. Blood
pressure was also measured in duplicate, but triplicate (or greater)
replications are now common in observational studies. Inherent
variability in these measures within and between individuals may
have attenuated their relationship with outcome. Results should be
evaluated within the context of the 95% confidence intervals, and
we do not have information on fasting glucose or HbA1c prior to
baseline. In addition, HbA1c was only moderately correlated with
fasting and post-load glucose measurements in this population
without diabetes; previous studies vary widely on the correspon-
dence of HbA1c with fasting glucose but the moderate correlation
observed here has been reported previously. It is possible that
studies with repeated measures of HbA1c may reveal modest
associations that this study missed. Additionally, echocardiograph-
ic measures of left ventricular diastolic function increasingly rely
upon tissue Doppler, which was not available during the studies in
this analysis, nor were alternative measures of arterial stiffness,
such as pulse wave velocity or the ß stiffness index. Nevertheless,
the non-invasive measures of ventricular and vascular stiffness
used herein have shown validity in other population-based cohorts
[30,31].
Although CHS is a population-based cohort study, participants
were generally healthy, community-dwelling older adults. More-
over, this substudy was conducted at the Wake Forest field center
and does not include participants from the other three centers. As
a result, our findings should be generalized to other populations
with an appropriate degree of caution.
In summary, our data do not provide evidence for an
association between HbA1c and arterial and ventricular stiffness
or subclinical atherosclerosis in a sample of community-living
older adults. It is possible that the half-life of HbA1c is too short,
and that measurement of more stable longer lasting AGEs may be
Table 3. Odds ratios and 95% confidence intervals for selected measures of stiffness/atherosclerosis, according to categories of
HbA1c and prevalent diabetes.
No. of subjects HbA1c 3.7–5.6% HbA1c 5.7–6.4% HbA1c 6.5–12.8%
Prevalent diabetes
defined by glucose or
medication use
(n=131)
Common carotid IMT $80%
age-gender-race- adjusted model 957 1.0 0.89 (0.57–1.37) 1.04 (0.66–1.65) 1.78 (1.08–2.92)
multivariable model
1 951 1.0 0.86 (0.55–1.34) 0.84 (0.52–1.35) 1.55 (0.91–2.63)
Internal carotid IMT $80%
age-gender-race- adjusted model 954 1.0 1.14 (0.74–1.77) 1.41 (0.89–2.22) 1.37 (0.81–2.33)
multivariable model
2 948 1.0 1.10 (0.70–1.73) 1.15 (0.71–1.87) 1.04 (0.59–1.84)
ABI ,.9 (vs. 0.9–1.4)
age-gender-race- adjusted model 926 1.0 0.81 (0.44–1.46) 0.64 (0.33–1.24) 1.27 (0.63–2.54)
multivariable model
2 921 1.0 0.79 (0.42–1.48) 0.45 (0.22–0.93) 0.95 (0.44–2.03)
Hypertension
age-gender-race- adjusted model 961 1.0 0.90 (0.65–1.25) 1.28 (0.89–1.84) 2.65 (1.64–4.30)
multivariable model
2 955 1.0 0.85 (0.61–1.19) 1.05 (0.71–1.54) 2.04 (1.23–3.38)
1Adjusted for age, gender, race (black, other), BMI, smoking status (never, former, current), total cholesterol, HDL cholesterol, antihypertensive medications, lipid-
lowering medications, C-reactive protein, and creatinine.
2Adjusted for all covariates in other multivariable models except for antihypertensive medications.
doi:10.1371/journal.pone.0047941.t003
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PLOS ONE | www.plosone.org 6 October 2012 | Volume 7 | Issue 10 | e47941required to detect associations with arterial stiffness and associated
comorbidities in individuals without diabetes. Alternatively, factors
other than AGE may be predominant determinants of arterial and
ventricular stiffness in this population, or circulating AGE may not
reflect AGE deposition in structural proteins.
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